Cooperative Agreement UG3HL176627
Award Date 8/1/25
Completion Date 7/31/26
Dollars Obligated $2.3M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Massachusetts, USA
Similar Awards
- The Cooperative Agreement award titled "STATINS TO PREVENT CANCER ASSOCIATED VENOUS THROMBOEMBOLISM (STAT-CAT): DCC - STAT-CAT" is funded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The $862,130 award will test whether the daily administration of the statin rosuvastatin can safely prevent venous thromboembolism (VTE) in cancer patients at high risk, who are not planned to receive anticoagulation therapy. The...
- The National Heart, Lung, and Blood Institute awarded a $721,826 Project Grant titled "Multi-Modal Dynamic Risk Prediction of Thrombosis and Bleeding in Patients with Cancer" under the Cardiovascular Diseases Research (CFDA 93.837) program. The project aims to leverage population science and data science methodologies to ascertain and predict thrombotic and hemorrhagic outcomes in approximately 330,000 cancer patients across three U.S. healthcare systems. The key products and...
- This $601,677 Project Grant award from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) will support a multi-scale study of the mechanisms underlying vaccine-induced immune thrombotic thrombocytopenia (VITT). The University of Massachusetts will conduct experimental and modeling research to characterize the formation of platelet-activating immune complexes and thrombus development triggered by adenoviral-vectored vaccines. The research aims...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Mercer University totals $657,602 and aims to investigate the direct vascular effects of statins on regulating blood pressure, including potential mechanisms involving phosphodiesterase 1A inhibition and cyclic GMP signaling. The research will be conducted on resistance mesenteric arteries from normotensive and hypertensive animal models, with the goal of...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $834,531 to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct research on the effects of IL-1 beta inhibition on vascular inflammation in individuals with clonal hematopoiesis of indeterminate potential (CHIP), a risk factor for atherosclerotic cardiovascular disease. The research aims to investigate vascular...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $494,283 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Botswana (UB) to develop and test new strategies to initiate statin therapy for people living with HIV (PWH) who also have hypertension in Botswana. The project, titled "Integrating Hypertension and Cardiovascular Disease Care into Existing HIV Service Package in Botswana (INTERCARE)-Statin Sub-Study," will leverage...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) aims to determine if cancer directly promotes cardiovascular disease and explore potential therapies. The $1,102,957 award to The Leland Stanford Junior University, commencing on April 15, 2025 and scheduled for completion on January 31, 2032, will fund a multidisciplinary research program across population genetics, cardio-oncology, and translational medicine. The...
- This $500,000 Project Grant award from the U.S. Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program supports research to improve understanding of delayed diagnosis of venous thromboembolism (VTE) in ambulatory care settings. The project aims to leverage electronic health record (EHR) data and stakeholder expertise to identify risk factors, disparities, and outcomes associated with delayed and missed VTE diagnosis in...
- This federal Project Grant award of $2,981,544.00, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), will fund a study to assess the impact of asymptomatic cytomegalovirus (CMV) infection on cardiovascular event risk in people with treated HIV infection. The study will leverage data from a prior clinical trial of the CMV-specific antiviral drug letermovir and a case-cohort study of over 1,900 ART-suppressed people with HIV to...
- This Cooperative Agreement was awarded by the National Heart, Lung, and Blood Institute (CFDA# 93.837 Cardiovascular Diseases Research) to Weill Medical College of Cornell University to conduct the "Randomized Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women (ROMA:Women)" trial. The $1,048,249 award, which runs from September 2025 to August 2026, will evaluate whether using multiple arterial grafts instead of single arterial grafts leads to better outcomes in...